3D DOSE ESCALATION FOR PROSTATE CANCER

前列腺癌的 3D 剂量递增

• 批准号: 2100975
• 负责人: Theodore Phillips
• 金额: $ 7.48万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-06-01 至 1997-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2100975
• 关键词: cancer information system; clinical trials; computer data analysis; cooperative study; cytotoxicity; data collection; human morbidity; human subject; human therapy evaluation; male; neoplasm /cancer radiation therapy; prostate neoplasms; radiation therapy dosage; seminal vesicles

This application is in response to a request for application for studies of the use of 3-D conformal radiotherapy (3DCRT) in the definitive treatment of prostate cancer. UCSF is prepared to work with the NCI, the operations and quality assurance center and other successful applicants in designing and conducting clinical trials of 3DCRT. It is expected that initial studies will be phase I/II dose searching protocols and that after these are completed a phase III trial will be designed and carried out. The local control rate in advanced prostate cancer is relatively low and (based on recent PSA and biopsy data) patients with more limited stages have a lower local control than previously thought. It is possible that the higher doses that are possible with 3DCRT without an increase in morbidity could lead to improved cure rates. UCSF has all of the required computer hardware and an excellent 3-D treatment planning system which meets all of the requirements of the RFA. It is expected that in 1992 the UCSF group will treat 144 prostate patients with curative intent. Since 1989 the group has treated 215 prostate patients with conformal plans, 109 with a 2.5-D system and 106 with the full 3-D system. Extensive analyses have been carried out of our experience which have yielded information on the risk of nodal metastases , selection of patients for trials evaluating local control, definition of margins to be treated around the prostate and evaluation of set-up variation. We analyzed various conformal and non-conformal plans with dose volume histograms and identified a 6 field conformal technique using partial transmission blocks which compared to more conventional non-conformal techniques, allows a potential increase in dose on the order of 20%. The experience of the group in treating this number of patients with CT conformal plans, our experience in the RTOG 3DCRT committee and the studies mentioned above will assist the UCSF group in working closely under the RFA group to design optimal protocols.

此申请是为了响应学习申请请求 3-D 适形放射治疗 (3DCRT) 在最终治疗中的应用 治疗前列腺癌。 UCSF 准备与 NCI 合作 运营和质量保证中心及其他成功申请者 设计和进行 3DCRT 的临床试验。 预计 初步研究将是 I/II 期剂量搜索方案并且 这些完成后，将设计并进行第三阶段试验 出去。 晚期前列腺癌的局部控制率相对较高 低且（基于最近的 PSA 和活检数据）患者的病情更有限 阶段的局部控制比之前想象的要低。 这是 3DCRT 无需使用 3DCRT 即可获得更高的剂量 发病率的增加可能会导致治愈率的提高。 UCSF 拥有所有 所需的计算机硬件和出色的 3D 治疗计划 该系统满足 RFA 的所有要求。 预计 1992 年 UCSF 小组将治疗 144 名前列腺患者 治疗意图。 自 1989 年以来，该小组已治疗了 215 名前列腺患者 具有共形计划，109 个具有 2.5-D 系统，106 个具有完整的 3-D 系统 系统。 我们对我们的经验进行了广泛的分析 已获得有关淋巴结转移风险、选择的信息 患者参加评估局部控制的试验，边缘的定义 前列腺周围的治疗和设置变化的评估。 我们 分析了各种保形和非保形计划的剂量体积 直方图并使用部分确定了 6 场共形技术 与更传统的非共形传输块相比 技术，允许剂量潜在增加 20% 左右。 这 小组治疗这么多CT患者的经验 保形计划、我们在 RTOG 3DCRT 委员会的经验以及 上述研究将有助于加州大学旧金山分校小组的密切合作 在 RFA 小组下设计最佳协议。